

Financial Tear Sheet

Corporate Profile

Accuray Incorporated is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The Company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.

Accuray does not assume a duty to update information on this website, except through the normal quarterly financial press releases and regulatory filings.

Stock Performance

ARAY (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$5.30
Change (%)	▲ 0.30 (6.00%)
Volume	1,062,169
52 Week Low	\$3.60
Market Cap	\$444,769,258
Rolling EPS	-0.35
PE Ratio	N/A
Shares Outstanding	83,918,728

Data as of Nov 22, 2017 4:00 p.m. ET



Press Releases

Nov 8, 2017 - 7:30 a.m.

Accuray Military Veterans Support U.S. Veteran
Community

Oct 26, 2017 - 7:31 a.m.

Treatment Planning for the CyberKnife® System
Now Up to 40% Faster

Oct 24, 2017 - 4:01 p.m.

Accuray Generated \$55.6 Million in First Quarter
Gross Orders; Revenue Increased 5 Percent Year
over Year

There are currently no events scheduled.

SEC Filings

Filing Date	Form	
Nov 20, 2017	8-K	
Nov 17, 2017	4	
Nov 17, 2017	4	
Nov 17, 2017	4	

Corporate Governance

Joshua H. Levine President and Chief Executive Officer

LIONEL HADJADJEBE CORPORATE SENIOR VICE PRESIDENT, CHIEF COMMERCIAL OFFICER

Kevin Waters Senior Vice President, Chief Financial Officer

Darl S. Moreland Senior Vice President, Regulatory, Quality and Compliance

Alaleh Nouri Senior Vice President, General Counsel and Corporate Secretary

Andy Kirkpatrick Senior Vice President, Global Operations and Corporate Development

Data provided by Nasdaq. Minimum 15 minutes delayed.

© 2007 - 2017 Accuray Incorporated. All Rights Reserved.